Evidence map›Paper›PMID 39629075›Full record

ArticleFrontiers in pharmacology2024

Preliminary investigation of the

Zhixiang Zhu, Yuanjing Zou, Ling Ou, Meiyun Chen, Yujiang Pang, Hui Li, Yajie Hao, Bingmei Su, Yuqian Lai, Liping Zhang and 5 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhixiang ZhuSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, China.
Yuanjing ZouSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Ling OuSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Meiyun ChenSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Yujiang PangSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, China.
Hui LiLunan Pharmaceutical Group Co., Ltd., Linyi, Shandong, China.
Yajie HaoLunan Pharmaceutical Group Co., Ltd., Linyi, Shandong, China.
Bingmei SuSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Yuqian LaiSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Liping ZhangLunan Pharmaceutical Group Co., Ltd., Linyi, Shandong, China.
Junwei JiaLunan Pharmaceutical Group Co., Ltd., Linyi, Shandong, China.
Ruixia WeiLunan Pharmaceutical Group Co., Ltd., Linyi, Shandong, China.
Guimin ZhangLunan Pharmaceutical Group Co., Ltd., Linyi, Shandong, China.
Meicun YaoSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China.
Zhong FengSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triphala, is a composite of three individual botanical drugs: Methods: Ours research investigates the Results: The research findings indicate that Triphala exhibits a minimum inhibitory concentration of 80-320 μg/mL against both standard and clinical strains of Discussion: These findings suggest that Triphala exerts inhibitory effects on

Indexed as

antimicrobial efficacyHelicobacter pylorimechanism of actionTriphalaurease

Identifiers

PMID39629075
PMCPMC11611552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.